Anthracyclines may produce cardiotoxicity by apoptosis and free radical formation. Carvedilol, in addition to being a nonselective beta-blocker and alpha 1 blocker, is antioxidant and antiapoptotic.
In recent years there has been considerable interest in the utilization of biomarkers to assist in the prediction of risk for cardiovascular events, including mortality.
The cardiotoxicity of anthracyclines and other agents may negatively affect clinical outcomes in cancer survivors. Data in other clinical situations and animal data on anthracycline-induced cardiomyopathy suggests that angiotensin-converting enzyme inhibitors (ACEI) may ameliorate this cardiotoxicity.
Sacher and colleagues collected data on all patients diagnosed with Brugada syndrome who received an implantable cardioverter defibrillator (ICD) in 14 centers between 1993 and 2005.
After 8-10 years, atherosclerosis of saphenous vein grafts and symptoms of ischemia are common. Since repeat bypass surgery is associated with a higher mortality than first surgeries, percutaneous interventions (PCI) are preferred for vein graft disease.
